The role of cetuximab in the therapy of previously treated advanced colorectal cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 9, 2005, Pages 55-58

  Chong, Geoff ^a   Cunningham, David ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ACNE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RASH;

EID: 30544455176     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.04.020     Document Type: Conference Paper

References (22)

1. A. Konishi, B.C. Berk Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells J Biol Chem 278 2003 35049 35056
2. Y. Yarden The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur J Cancer 37 suppl 4 2001 S3 S8
3. C. Messa, F. Russo, M.G. Caruso EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma Acta Oncol 37 1998 285 289
4. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
5. A. Mayer, M. Takimoto, E. Fritz The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer 71 1993 2454 2460
6. J. Mendelsohn, J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
7. B.F. El Rayes, P.M. LoRusso Targeting the epidermal growth factor receptor Br J Cancer 91 2004 418 424
8. S.R. Datta, H. Dudek, X. Tao Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
9. M.H. Cardone, N. Roy, H.R. Stennicke Regulation of cell death protease caspase-9 by phosphorylation Science 282 1998 1318 1321
10. S.W. Fesik Insights into programmed cell death through structural biology Cell 103 2000 273 282
11. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
12. M. Prewett, P. Rockwell, R.F. Rockwell The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma J Immunother Emphasis Tumor Immunol 19 1996 419 427
13. A.M. Petit, J. Rak, M.C. Hung Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo Angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1997 1523 1530
14. T. Matsumoto, P. Perrotte, M. Bar-Eli Blockade of EGF-R signaling with anti-EGFR monoclonal antibody C225 inhibits matrix metalloproteinase-9 expression and invasion of human transitional cell carcinoma in vitro and in vivo Proc Am Assoc Cancer Res 39 1998 83 (abstr)
15. L.B. Saltz, M. Rubin, H. Hochster Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor Proc Am Soc Clin Oncol 20 2001 3a (abstr 7)
16. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
17. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
18. H.J. Lenz, R.J. Mayer, P.J. Gold Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin Proc Am Soc Clin Oncol 23 2004 248 (abstr 3510)
19. L.B. Saltz, M. Kies, J.L. Abbruzzesse The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies Proc Am Soc Clin Oncol 22 2003 204 (abstr 817)
20. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
21. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
22. S. Badarinath, E.P. Mitchell, A. Jennis Cetuximab plus FOLFOX for colorectal cancer (EXPLORE) Preliminary safety analysis of a randomized phase III trial Proc Am Soc Clin Oncol 23 2004 253 (abstr 3531)